Treatment of erosive vulvovaginal lichen planus with tofacitinib: A case series

Abstract

Lichen planus (LP) is a chronic inflammatory skin disease that affects cutaneous and mucosal sites and is often recalcitrant to topical therapies. Erosive lichen planus (ELP) is a severe variant which is often less responsive to therapy. ELP tends to occur on the oral and anogenital mucosa and modified mucous membranes but can also involve other mucosal sites, such as the esophagus. ELP significantly affects quality of life (QOL) and if left untreated, can lead to chronic scarring.1 Erosive vulvovaginal LP (EVVLP) can lead to narrowing of the introitus and midline fusion, resulting in pain, itch, irritation, dyspareunia, dysuria, and recurrent urinary tract infections due to urinary retention and obstruction.